CN102648906A - 舒尼替尼在制备乙酰胆碱酯酶抑制剂中的应用 - Google Patents

舒尼替尼在制备乙酰胆碱酯酶抑制剂中的应用 Download PDF

Info

Publication number
CN102648906A
CN102648906A CN2012101537630A CN201210153763A CN102648906A CN 102648906 A CN102648906 A CN 102648906A CN 2012101537630 A CN2012101537630 A CN 2012101537630A CN 201210153763 A CN201210153763 A CN 201210153763A CN 102648906 A CN102648906 A CN 102648906A
Authority
CN
China
Prior art keywords
sunitinib
ko
disease
preparation
choline
Prior art date
Application number
CN2012101537630A
Other languages
English (en)
Chinese (zh)
Inventor
杨永亮
毛磊
牛铭山
Original Assignee
大连理工大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大连理工大学 filed Critical 大连理工大学
Priority to CN2012101537630A priority Critical patent/CN102648906A/zh
Publication of CN102648906A publication Critical patent/CN102648906A/zh

Links

CN2012101537630A 2012-05-17 2012-05-17 舒尼替尼在制备乙酰胆碱酯酶抑制剂中的应用 CN102648906A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2012101537630A CN102648906A (zh) 2012-05-17 2012-05-17 舒尼替尼在制备乙酰胆碱酯酶抑制剂中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2012101537630A CN102648906A (zh) 2012-05-17 2012-05-17 舒尼替尼在制备乙酰胆碱酯酶抑制剂中的应用

Publications (1)

Publication Number Publication Date
CN102648906A true CN102648906A (zh) 2012-08-29

Family

ID=46691141

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012101537630A CN102648906A (zh) 2012-05-17 2012-05-17 舒尼替尼在制备乙酰胆碱酯酶抑制剂中的应用

Country Status (1)

Country Link
CN (1) CN102648906A (ru)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101022799A (zh) * 2004-07-19 2007-08-22 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
WO2010017541A2 (en) * 2008-08-08 2010-02-11 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101022799A (zh) * 2004-07-19 2007-08-22 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
WO2010017541A2 (en) * 2008-08-08 2010-02-11 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease

Similar Documents

Publication Publication Date Title
Roos et al. 5-hydroxyindoleacetic acid (and homovanillic acid) levels in the cerebrospinal fluid after probenecid application in patiens with manic-depressive psychosis
Abrams et al. Muscarinic receptor antagonists for overactive bladder
Hegde Muscarinic receptors in the bladder: from basic research to therapeutics
Barbeau The pathogenesis of Parkinson's disease: a new hypothesis
Nagakura et al. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia
Dedeoglu et al. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis
Shibata et al. The herbal medicine Dai-Kenchu-Tou stimulates upper gut motility through cholinergic and 5-hydroxytryptamine 3 receptors in conscious dogs
Facemire et al. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression
Ding et al. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability
Bymaster et al. Muscarinic receptors as a target for drugs treating schizophrenia
Sun et al. Carbonic anhydrase gating of attention: memory therapy and enhancement
Hooper et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis
ES2410930T3 (es) Nuevos enfoques terapéuticos para tratar la enfermedad de alzheimer y trastornos relacionados mediante la modulación de la respuesta de estrés celular
CA2335012C (en) Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
Peer et al. Randomised crossover trial of naltrexone in uraemic pruritus
Hanson et al. The methamphetamine experience: a NIDA partnership
US6232326B1 (en) Treatment for schizophrenia and other dopamine system dysfunctions
Park et al. Chemotherapy‐induced peripheral neurotoxicity: a critical analysis
Chang et al. Hiccup: mystery, nature and treatment
Walker et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias
Tang et al. Autophagy reduces neuronal damage and promotes locomotor recovery via inhibition of apoptosis after spinal cord injury in rats
Gao et al. Geniposide Ameliorates Learning Memory Deficits, Reduces Tau Phosphorylation and Decreases Apoptosis via GSK 3β Pathway in Streptozotocin‐Induced A lzheimer Rat Model
Hollander et al. Cholinergic approaches to the treatment of Alzheimer's disease
Bentue-Ferrer et al. Clinically significant drug interactions with cholinesterase inhibitors
Besser et al. End‐plate dysfunction in acute organophosphate intoxication

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
C12 Rejection of a patent application after its publication